CurrentMedical Mutual - OhioPolicy N/A

Imvexxy (estradiol vaginal insert) coverage

Defines prior authorization and coverage criteria for Imvexxy for treatment of moderate to severe dyspareunia from vulvar and vaginal atrophy in postmenopausal women, for Medical Mutual - Ohio commercial formularies.

Policy Summary

PayerMedical Mutual - Ohio

PolicyImvexxy (estradiol vaginal insert) coverage

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateJun 19, 2025

Key ActionPrior authorization is recommended for pharmacy benefit coverage; ensure documentation supports prior trial of at least one low-dose vaginal estrogen.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3 monthsinitial approval duration

1 yearextended approval duration

prior authauthorization requirement

trial ≥1 low‑dose estrogenstep required

Coverage / Medical Necessity Criteria

inv-01: Initial Authorization Criteria

Covered when ALL of the following are met for initial therapy:

Population: Patient is a post-menopausal woman with vulvar and/or vaginal atrophy

from criteria 1.A

Prior therapy: Patient has had an inadequate response to at least one low-dose vaginal estrogen preparation (examples: generic estrogen vaginal cream, generic estrogen vaginal insert, Yuvafem, Premarin vaginal cream, Estrace vaginal cream, Estring, Vagifem)

from criteria 1.B

Contraindications absent: Patient does not have any contraindications to use of estrogens (examples: history of breast cancer, estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, liver disease/impairment, history of or active DVT, PE, stroke, or MI)

from criteria 1.C

Policy Summary

PayerMedical Mutual - Ohio

PolicyImvexxy (estradiol vaginal insert) coverage

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateJun 19, 2025

Key ActionPrior authorization is recommended for pharmacy benefit coverage; ensure documentation supports prior trial of at least one low-dose vaginal estrogen.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Monotherapy: Imvexxy will not be used in combination with other estrogen preparations, Osphena, or Intrarosa

from criteria 1.D

inv-02: Continuation/Extended Authorization Criteria

Covered for continuation when ALL of the following are met:

Existing patient criteria: The patient meets all initial start criteria

from criteria section 2.A

Clinical response: The patient has had an improvement on Imvexxy per the prescribing physician

from criteria section 2.B

Coverage is limited to the circumstances explicitly described in the Recommended Authorization Criteria. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. This list is not exhaustive and may be updated as new published data become available; reviewers should consult the most recent policy version when making coverage decisions.

Initial Therapy

inv-10: Initial Therapy — Initial approval provided when initial authorization criteria are met

Initial approval is provided when initial authorization criteria are met:

Population and prior therapy: Post-menopausal woman with vulvar and/or vaginal atrophy AND inadequate response to at least one low-dose vaginal estrogen preparation

criteria 1.A and 1.B

Contraindications absent: No contraindications to estrogens as described in the authorization criteria

criteria 1.C

Continuation Therapy

inv-11: Continuation Therapy — continuation (patients already started on Imvexxy)

Continuation (patients already started on Imvexxy):

Meets initial criteria: Patient meets all criteria for new starts

criteria 2.A

Clinical improvement: Patient has had an improvement on Imvexxy per the prescribing physician

criteria 2.B

Provider Requirements & Prior Authorization

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for pharmacy benefit coverage of Imvexxy. Approval is recommended for those who meet the coverage criteria in this policy. Initial approvals are provided for the duration noted in the policy; reauthorization requires documentation of response to therapy when continuation is allowed.

Step Therapy

Required Trial of Low‑Dose Vaginal Estrogen

Patient must have had an inadequate response to at least one low‑dose vaginal estrogen preparation prior to authorization of Imvexxy. Examples include generic estrogen vaginal cream, generic estrogen vaginal insert, Yuvafem, Premarin vaginal cream, Estrace vaginal cream, Estring, and Vagifem.

Examples: generic estrogen vaginal cream, generic estrogen vaginal insert, Yuvafem, Premarin vaginal cream, Estrace vaginal cream, Estring, Vagifem

Documentation Required

Documentation Must Be Supplied on Request

The Company may request additional documentation to support medical necessity. Providers must make available clinical records, test results, and provider credentials upon request to substantiate the need for Imvexxy.

Provide clinical notes documenting diagnosis and prior therapies
Provide test results or other objective findings if requested
Supply provider credentials upon request

Denial Risk

Denial Risk for Insufficient Medical Necessity or Eligibility

The Company may deny reimbursement when the drug is not medically necessary, is investigational or experimental, is not within the member's benefits, or when billing or practice patterns are inappropriate or excessive. The Company reserves the right to modify or interpret this policy at its sole discretion.

Denial reasons include: not medically necessary, investigational/experimental, not within benefits, inappropriate or excessive billing patterns

Step Therapy Requirements

Step	Requirement
1	Trial of ≥1 low‑dose vaginal estrogen product (examples: generic estrogen vaginal cream, generic estrogen vaginal insert, Yuvafem, Premarin vaginal cream, Estrace vaginal cream, Estring, Vagifem) with inadequate response prior to Imvexxy

Key Definitions

inv-09: Dyspareunia due to vulvar and vaginal atrophy — labeled indication for Imvexxy

Defined termModerate to severe dyspareunia resulting from vulvar and vaginal atrophy (menopausal symptom)

Drug indicationLabeled indication for Imvexxy (estradiol vaginal insert)

Target populationPost‑menopausal women with vulvar and/or vaginal atrophy experiencing dyspareunia

Clinical Background

Imvexxy (estradiol vaginal insert) is indicated for the treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women. The policy addresses Imvexxy as a vaginal estradiol therapy option for this labeled indication and frames coverage around prior use of low‑dose vaginal estrogen and absence of estrogen contraindications.